Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed on 389 tumor blocks from three large adjuvant trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Edith A., Press, Michael F., Dueck, Amylou C., Jenkins, Robert B., Kim, Chungyeul, Chen, Beiyun, Villalobos, Ivonne, Paik, Soonmyung, Buyse, Marc, Wiktor, Anne E., Meyer, Reid, Finnigan, Melanie, Zujewski, JoAnne, Shing, Mona, Stern, Howard M., Lingle, Wilma L., Reinholz, Monica M., Slamon, Dennis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585916/
https://www.ncbi.nlm.nih.gov/pubmed/23420271
http://dx.doi.org/10.1007/s10549-013-2444-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585916/
https://www.ncbi.nlm.nih.gov/pubmed/23420271
http://dx.doi.org/10.1007/s10549-013-2444-y

Ejemplares similares